目的观察渗漏点位于黄斑中心凹500µm范围之内的急性中心性浆液性脉络膜视网膜病变(CSC)患者行577 nm阈下微脉冲激光治疗(SML)后黄斑区结构及微循环的变化。方法回顾性病例研究。纳入2022年8月至2023年10月在苏北人民医院眼科确诊...目的观察渗漏点位于黄斑中心凹500µm范围之内的急性中心性浆液性脉络膜视网膜病变(CSC)患者行577 nm阈下微脉冲激光治疗(SML)后黄斑区结构及微循环的变化。方法回顾性病例研究。纳入2022年8月至2023年10月在苏北人民医院眼科确诊为急性CSC且渗漏点位于黄斑中心凹500µm范围之内的患者36例(36只眼)。患眼均行SML治疗,记录所有急性CSC患者行SML治疗前、治疗后1个月、3个月的最佳矫正视力(BCVA)、相干光层析成像术(OCT)及相干光层析血管成像术(OCTA)检查相关指标,对比研究急性CSC患眼经SML治疗前后黄斑区形态及微循环指标的变化。结果(1)本组急性CSC患眼在接受SML治疗后3个月的患眼视力显著提高(P<0.001)。接受SML治疗后1个月和3个月患眼的黄斑中心凹视网膜厚度(CMT)均显著降低(均P<0.05)。接受SML治疗后1个月和3个月患眼的黄斑中心凹下脉络膜厚度(SFCT)均明显降低(均P<0.05)。(2)本组急性CSC患眼经SML治疗后脉络膜毛细血管血流密度(CCVD)水平呈上升趋势,但仅治疗后3个月相比于治疗后1个月CCVD显著提升(P<0.05)。本组急性CSC患眼SML治疗后3个月,黄斑区浅层视网膜毛细血管血流密度(SCPVD)、黄斑区深层视网膜毛细血管血流密度(DCPVD)均较治疗前显著降低(均P<0.05)。(3)与治疗前相比,经SML治疗后1个月和3个月患眼的环绕黄斑无血管区面积(FAZ)区域300µm范围内的血流密度(vessel density around the FAZ-300,FD-300)均显著提高(均P<0.05)。结论对于渗漏点位于黄斑中心凹500µm之内的急性CSC患者,SML可快速降低患眼黄斑CMT及SFCT,逐步增加脉络膜毛细血管血流密度,降低中心凹浅层与深层视网膜毛细血管血流密度。展开更多
BACKGROUND Circular RNAs(circRNAs)are critical regulators in tumorigenesis,functioning as microRNA sponges or protein decoys.Although numerous circRNAs have been implicated in gastric cancer progression,the role of hs...BACKGROUND Circular RNAs(circRNAs)are critical regulators in tumorigenesis,functioning as microRNA sponges or protein decoys.Although numerous circRNAs have been implicated in gastric cancer progression,the role of hsa_circRNA_101996 remains unclear.This study hypothesizes that hsa_circRNA_101996 promotes gastric cancer cell proliferation and apoptosis via the microRNA-577(miR-577)/high mobility group nucleosome binding domain 5(HMGN5)axis.AIM To investigate the role of hsa_circRNA_101996 in gastric cancer proliferation and apoptosis through the miR-577/HMGN5 axis.METHODS Forty-one paired gastric cancer tissues and adjacent non-cancerous tissues were analyzed.Differential circRNA expression was identified using GSE83521 and GSE89143 datasets.miR-577 and HMGN5 were predicted via CircInteractome and TargetScan.Functional experiments(MTT,colony formation,Western blot)and dual-luciferase reporter assays were performed in gastric cancer cell lines(OCUM-1,HSC-39).In vivo tumorigenesis was validated in nude mice.Statistical analysis included Student’s t-test and one-way ANOVA(P<0.05).RESULTS Hsa_circRNA_101996 was significantly upregulated in gastric cancer tissues and cell lines compared to adjacent non-cancerous tissues(P<0.05).Dual-luciferase reporter assays validated the interactions among hsa_circRNA_101996,miR-577,and HMGN5.In vitro,gastric cancer cells overexpressing hsa_circRNA_101996 showed significantly increased proliferation and decreased apoptosis compared to controls(P<0.05).Cells transfected with miR-577 mimics exhibited reduced proliferation and increased apoptosis(P<0.05).Co-transfection with hsa_circRNA_101996 or HMGN5 reversed the effects of miR-577 mimics.In vivo,hsa_circRNA_101996-overexpressing tumors showed increased volume and HMGN5 expression(P<0.05).CONCLUSION Hsa_circRNA_101996 promotes gastric cancer progression by sponging miR-577 to upregulate HMGN5,suggesting a novel therapeutic target for gastric cancer.展开更多
AIM:To evaluate the efficacy and safety of conbercept combined with 577 nm subthreshold micropulse laser(STML)for treatment of diabetic macular edema(DME).METHODS:A retrospective study was conducted.From October 2022 ...AIM:To evaluate the efficacy and safety of conbercept combined with 577 nm subthreshold micropulse laser(STML)for treatment of diabetic macular edema(DME).METHODS:A retrospective study was conducted.From October 2022 to March 2024,72 patients diagnosed with DME at the outpatient clinic were enrolled.The patients were divided into two groups:the simple group(treated with conbercept alone)and the combination group(treated with 577 nm STML combined with conbercept).The following itmes were compared between the two groups:best corrected visual acuity(BCVA),central macular thickness(CMT),foveal avascular zone(FAZ),vessel density of the superficial capillary plexus(SCP)and deep capillary plexus(DCP),retinal mean sensitivity(RMS),injection numbers,and the number of cases with adverse effects.RESULTS:The mean age of patients was 57.13±8.76(range 34-77)y with DR history of 0.89±0.55y.With the progression of treatment,both groups showed significant improvements in BCVA,CMT,DCP vessel density,and RMS compared to baselines(all,P<0.05).At 3 and 6mo after treatment,the combination group exhibited significantly better outcomes in BCVA,CMT,DCP vessel density,and RMS than the simple group(P<0.05).During the treatment period,neither group showed significant improvements in FAZ and SCP vessel density(P>0.05),and no significant differences in FAZ and SCP vessel density were observed between the two groups(P>0.05).The average number of injections required in the combination group was lower than that in the simple group(3.33±0.68 vs 4.06±0.96,P<0.05).No other serious ophthalmic adverse events were observed in either group.CONCLUSION:Conbercept combined with STML has better outcomes for treatment of DME and less intravitreal injections compared to conbercept monotherapy.展开更多
目的:分析577nm微脉冲激光(SML)光凝联合玻璃体腔注射康柏西普治疗增殖性糖尿病视网膜病变(PDR)患者玻璃体切除术后发生糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析2019-01/2021-06就诊于我院经玻璃体切除治疗的PDR患者,术后发生...目的:分析577nm微脉冲激光(SML)光凝联合玻璃体腔注射康柏西普治疗增殖性糖尿病视网膜病变(PDR)患者玻璃体切除术后发生糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析2019-01/2021-06就诊于我院经玻璃体切除治疗的PDR患者,术后发生DME患者29例30眼。根据治疗方式不同分为两组,单纯注射组患者14例14眼行玻璃体腔注射康柏西普,联合治疗组患者15例16眼行黄斑区577nm微脉冲激光光凝联合玻璃体腔注射康柏西普。比较两组患者治疗前及治疗6、12mo最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)的变化,以及治疗前、治疗12mo多焦视网膜电流图(mfERG)的变化。结果:两组患者治疗6、12mo BCVA(LogMAR)均较术前改善,CMT均较术前下降(均P<0.001)。单纯注射组治疗前及治疗6、12mo BCVA(LogMAR)、CMT与联合治疗组比较均无差异(均P>0.05)。治疗12mo单纯注射组较联合治疗组振幅略低(23.02±3.13 vs 26.50±3.33μV/deg2),潜伏期延长(38.75±1.62 vs 34.21±3.06ms)(均P≤0.001)。随访12mo,单纯注射组注射康柏西普8.14±1.46次,联合治疗组5.05±1.51次(P<0.05)。结论:577nm微脉冲激光光凝联合玻璃体腔注射康柏西普可有效缓解玻璃体切除术后DME患者的黄斑水肿、提高BCVA,并能改善黄斑区视功能,有效减少康柏西普注射次数。展开更多
目的探讨miR-577在幼儿复发性喉乳头状瘤中的表达及其对细胞增殖、侵袭的影响和潜在分子机制。方法收集2016年6月至2019年12月确诊的30例幼儿喉乳头状瘤组织样本及其相匹配且远离病灶经病理检查证实的正常喉组织样本,并选取人正常喉上...目的探讨miR-577在幼儿复发性喉乳头状瘤中的表达及其对细胞增殖、侵袭的影响和潜在分子机制。方法收集2016年6月至2019年12月确诊的30例幼儿喉乳头状瘤组织样本及其相匹配且远离病灶经病理检查证实的正常喉组织样本,并选取人正常喉上皮细胞株和喉乳头状瘤细胞(分为miR-577过表达组、阴性对照组及空白对照组)进行研究。采用实时荧光定量PCR(qRT-PCR)分别检测30例喉乳头状瘤组织、配对正常喉组织、正常喉上皮细胞和喉乳头状瘤细胞中miR-577相对表达;通过Lipofectamine^(TM)3000脂质体转染试剂盒将miR-577 mimic模拟物转染至喉乳头状瘤细胞构建miR-577过表达细胞系,采用CCK-8法、Tanswell实验分别检测miR-577对喉乳头状瘤细胞增殖、侵袭的影响;采用Western blot检测miR-577对喉乳头状瘤细胞侵袭相关蛋白(MMP-1、MMP-9)表达及Notch通路相关蛋白(Notch、DSL)表达的影响。结果幼儿喉乳头状瘤组织中miR-577相对表达量(0.134±0.026)显著低于正常喉组织(0.823±0.056)(P<0.001);喉乳头状瘤细胞中miR-577相对表达量(0.256±0.026)显著低于正常喉上皮细胞(0.962±0.072)(P<0.001);与阴性对照组相比,转染miR-577 mimic后喉乳头状瘤细胞增殖能力(1.248±0.103 vs 0.902±0.094)和细胞侵袭率(71.016±5.869 vs 42.867±4.795)明显降低(P<0.05);侵袭相关蛋白MMP-1(1.011±0.124 vs 0.417±0.056)、MMP-9(1.012±0.155 vs 0.502±0.058)表达抑制(P<0.01)。喉乳头状瘤细胞中Notch、DSL表达显著上调(P<0.05);转染miR-577 mimic后喉乳头状瘤细胞中Notch通路相关蛋白Notch、DSL表达明显抑制(P<0.05)。共转染miR-577 mimic和pcDNA3.1-Notch后喉乳头状瘤细胞增殖能力和细胞侵袭率较单纯转染miR-577 mimic组明显增加(P<0.05);共转染pcDNA3.1-Notch逆转了miR-577 mimic对喉乳头状瘤细胞增殖、侵袭能力的抑制作用。结论幼儿喉乳头状瘤组织及喉乳头状瘤细胞中miR-577显著低表达,过表达miR-577显著抑制喉乳头状瘤细胞的增殖和侵袭;Notch是miR-577的潜在靶点,miR-577可能通过与Notch的3'UTR区结合进而调控Notch信号通路来抑制喉乳头状瘤细胞的增殖和侵袭。展开更多
目的:探讨利用577nm阈值下微脉冲激光治疗糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析48例64眼DME患者临床资料,行577nm阈值下微脉冲激光术者26例35眼,行传统格栅样激光术者22例29眼。比较术前及术后1、3、6mo时BCVA(LogMAR)、...目的:探讨利用577nm阈值下微脉冲激光治疗糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析48例64眼DME患者临床资料,行577nm阈值下微脉冲激光术者26例35眼,行传统格栅样激光术者22例29眼。比较术前及术后1、3、6mo时BCVA(LogMAR)、黄斑中心凹视网膜厚度(CFT)、平均光敏感度(MS)及平均视野缺损(MD)变化,分析两组患者眼底硬性渗出持续时间及并发症。结果:术后1、3、6mo时,两组视力(0.30±0.09 vs 0.35±0.10、0.19±0.07 vs 0.26±0.09、0.13±0.04 vs 0.18±0.05)及CFT (349.26±21.80μm vs 364.37±23.91μm、314.46±20.49μm vs 335.07±22.68μm、328.35±21.74μm vs 352.43±23.60μm)均较术前下降,且观察组明显低于同一时间对照组(均P<0.05);观察组MS、MD水平均较术前提升,且明显高于同一时间对照组5.83±1.16dB vs 4.22±1.04dB、6.38±1.29dB vs 4.49±1.17dB、6.75±1.22dB vs 4.68±1.20dB,-5.53±1.41dB vs-7.66±1.52dB、-5.09±1.30dB vs-7.26±1.39dB、-4.68±1.14dB vs-7.05±1.26dB)(均P<0.05)。观察组眼底硬性渗出持续时间明显少于对照组(3.39±0.80mo vs 4.25±1.14mo)(P<0.05)。术后6mo内,观察组眼球疼痛发生率明显低于对照组[3%(1/35)vs 24%(7/29)](P<0.05),而前房炎性反应、视野缺损、高眼压及角膜水肿发生率比较均无差异(P>0.05)。结论:577nm阈值下微脉冲激光术治疗DME安全有效。展开更多
文摘目的观察渗漏点位于黄斑中心凹500µm范围之内的急性中心性浆液性脉络膜视网膜病变(CSC)患者行577 nm阈下微脉冲激光治疗(SML)后黄斑区结构及微循环的变化。方法回顾性病例研究。纳入2022年8月至2023年10月在苏北人民医院眼科确诊为急性CSC且渗漏点位于黄斑中心凹500µm范围之内的患者36例(36只眼)。患眼均行SML治疗,记录所有急性CSC患者行SML治疗前、治疗后1个月、3个月的最佳矫正视力(BCVA)、相干光层析成像术(OCT)及相干光层析血管成像术(OCTA)检查相关指标,对比研究急性CSC患眼经SML治疗前后黄斑区形态及微循环指标的变化。结果(1)本组急性CSC患眼在接受SML治疗后3个月的患眼视力显著提高(P<0.001)。接受SML治疗后1个月和3个月患眼的黄斑中心凹视网膜厚度(CMT)均显著降低(均P<0.05)。接受SML治疗后1个月和3个月患眼的黄斑中心凹下脉络膜厚度(SFCT)均明显降低(均P<0.05)。(2)本组急性CSC患眼经SML治疗后脉络膜毛细血管血流密度(CCVD)水平呈上升趋势,但仅治疗后3个月相比于治疗后1个月CCVD显著提升(P<0.05)。本组急性CSC患眼SML治疗后3个月,黄斑区浅层视网膜毛细血管血流密度(SCPVD)、黄斑区深层视网膜毛细血管血流密度(DCPVD)均较治疗前显著降低(均P<0.05)。(3)与治疗前相比,经SML治疗后1个月和3个月患眼的环绕黄斑无血管区面积(FAZ)区域300µm范围内的血流密度(vessel density around the FAZ-300,FD-300)均显著提高(均P<0.05)。结论对于渗漏点位于黄斑中心凹500µm之内的急性CSC患者,SML可快速降低患眼黄斑CMT及SFCT,逐步增加脉络膜毛细血管血流密度,降低中心凹浅层与深层视网膜毛细血管血流密度。
文摘BACKGROUND Circular RNAs(circRNAs)are critical regulators in tumorigenesis,functioning as microRNA sponges or protein decoys.Although numerous circRNAs have been implicated in gastric cancer progression,the role of hsa_circRNA_101996 remains unclear.This study hypothesizes that hsa_circRNA_101996 promotes gastric cancer cell proliferation and apoptosis via the microRNA-577(miR-577)/high mobility group nucleosome binding domain 5(HMGN5)axis.AIM To investigate the role of hsa_circRNA_101996 in gastric cancer proliferation and apoptosis through the miR-577/HMGN5 axis.METHODS Forty-one paired gastric cancer tissues and adjacent non-cancerous tissues were analyzed.Differential circRNA expression was identified using GSE83521 and GSE89143 datasets.miR-577 and HMGN5 were predicted via CircInteractome and TargetScan.Functional experiments(MTT,colony formation,Western blot)and dual-luciferase reporter assays were performed in gastric cancer cell lines(OCUM-1,HSC-39).In vivo tumorigenesis was validated in nude mice.Statistical analysis included Student’s t-test and one-way ANOVA(P<0.05).RESULTS Hsa_circRNA_101996 was significantly upregulated in gastric cancer tissues and cell lines compared to adjacent non-cancerous tissues(P<0.05).Dual-luciferase reporter assays validated the interactions among hsa_circRNA_101996,miR-577,and HMGN5.In vitro,gastric cancer cells overexpressing hsa_circRNA_101996 showed significantly increased proliferation and decreased apoptosis compared to controls(P<0.05).Cells transfected with miR-577 mimics exhibited reduced proliferation and increased apoptosis(P<0.05).Co-transfection with hsa_circRNA_101996 or HMGN5 reversed the effects of miR-577 mimics.In vivo,hsa_circRNA_101996-overexpressing tumors showed increased volume and HMGN5 expression(P<0.05).CONCLUSION Hsa_circRNA_101996 promotes gastric cancer progression by sponging miR-577 to upregulate HMGN5,suggesting a novel therapeutic target for gastric cancer.
基金Supported by Henan Province Youth Health Science and Technology Innovation Talent Training Project(No.LJRC2023008)The Key Scientific Research Projects Plan of Universities in Henan Province(No.24A320040).
文摘AIM:To evaluate the efficacy and safety of conbercept combined with 577 nm subthreshold micropulse laser(STML)for treatment of diabetic macular edema(DME).METHODS:A retrospective study was conducted.From October 2022 to March 2024,72 patients diagnosed with DME at the outpatient clinic were enrolled.The patients were divided into two groups:the simple group(treated with conbercept alone)and the combination group(treated with 577 nm STML combined with conbercept).The following itmes were compared between the two groups:best corrected visual acuity(BCVA),central macular thickness(CMT),foveal avascular zone(FAZ),vessel density of the superficial capillary plexus(SCP)and deep capillary plexus(DCP),retinal mean sensitivity(RMS),injection numbers,and the number of cases with adverse effects.RESULTS:The mean age of patients was 57.13±8.76(range 34-77)y with DR history of 0.89±0.55y.With the progression of treatment,both groups showed significant improvements in BCVA,CMT,DCP vessel density,and RMS compared to baselines(all,P<0.05).At 3 and 6mo after treatment,the combination group exhibited significantly better outcomes in BCVA,CMT,DCP vessel density,and RMS than the simple group(P<0.05).During the treatment period,neither group showed significant improvements in FAZ and SCP vessel density(P>0.05),and no significant differences in FAZ and SCP vessel density were observed between the two groups(P>0.05).The average number of injections required in the combination group was lower than that in the simple group(3.33±0.68 vs 4.06±0.96,P<0.05).No other serious ophthalmic adverse events were observed in either group.CONCLUSION:Conbercept combined with STML has better outcomes for treatment of DME and less intravitreal injections compared to conbercept monotherapy.
文摘目的:分析577nm微脉冲激光(SML)光凝联合玻璃体腔注射康柏西普治疗增殖性糖尿病视网膜病变(PDR)患者玻璃体切除术后发生糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析2019-01/2021-06就诊于我院经玻璃体切除治疗的PDR患者,术后发生DME患者29例30眼。根据治疗方式不同分为两组,单纯注射组患者14例14眼行玻璃体腔注射康柏西普,联合治疗组患者15例16眼行黄斑区577nm微脉冲激光光凝联合玻璃体腔注射康柏西普。比较两组患者治疗前及治疗6、12mo最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)的变化,以及治疗前、治疗12mo多焦视网膜电流图(mfERG)的变化。结果:两组患者治疗6、12mo BCVA(LogMAR)均较术前改善,CMT均较术前下降(均P<0.001)。单纯注射组治疗前及治疗6、12mo BCVA(LogMAR)、CMT与联合治疗组比较均无差异(均P>0.05)。治疗12mo单纯注射组较联合治疗组振幅略低(23.02±3.13 vs 26.50±3.33μV/deg2),潜伏期延长(38.75±1.62 vs 34.21±3.06ms)(均P≤0.001)。随访12mo,单纯注射组注射康柏西普8.14±1.46次,联合治疗组5.05±1.51次(P<0.05)。结论:577nm微脉冲激光光凝联合玻璃体腔注射康柏西普可有效缓解玻璃体切除术后DME患者的黄斑水肿、提高BCVA,并能改善黄斑区视功能,有效减少康柏西普注射次数。
文摘目的探讨miR-577在幼儿复发性喉乳头状瘤中的表达及其对细胞增殖、侵袭的影响和潜在分子机制。方法收集2016年6月至2019年12月确诊的30例幼儿喉乳头状瘤组织样本及其相匹配且远离病灶经病理检查证实的正常喉组织样本,并选取人正常喉上皮细胞株和喉乳头状瘤细胞(分为miR-577过表达组、阴性对照组及空白对照组)进行研究。采用实时荧光定量PCR(qRT-PCR)分别检测30例喉乳头状瘤组织、配对正常喉组织、正常喉上皮细胞和喉乳头状瘤细胞中miR-577相对表达;通过Lipofectamine^(TM)3000脂质体转染试剂盒将miR-577 mimic模拟物转染至喉乳头状瘤细胞构建miR-577过表达细胞系,采用CCK-8法、Tanswell实验分别检测miR-577对喉乳头状瘤细胞增殖、侵袭的影响;采用Western blot检测miR-577对喉乳头状瘤细胞侵袭相关蛋白(MMP-1、MMP-9)表达及Notch通路相关蛋白(Notch、DSL)表达的影响。结果幼儿喉乳头状瘤组织中miR-577相对表达量(0.134±0.026)显著低于正常喉组织(0.823±0.056)(P<0.001);喉乳头状瘤细胞中miR-577相对表达量(0.256±0.026)显著低于正常喉上皮细胞(0.962±0.072)(P<0.001);与阴性对照组相比,转染miR-577 mimic后喉乳头状瘤细胞增殖能力(1.248±0.103 vs 0.902±0.094)和细胞侵袭率(71.016±5.869 vs 42.867±4.795)明显降低(P<0.05);侵袭相关蛋白MMP-1(1.011±0.124 vs 0.417±0.056)、MMP-9(1.012±0.155 vs 0.502±0.058)表达抑制(P<0.01)。喉乳头状瘤细胞中Notch、DSL表达显著上调(P<0.05);转染miR-577 mimic后喉乳头状瘤细胞中Notch通路相关蛋白Notch、DSL表达明显抑制(P<0.05)。共转染miR-577 mimic和pcDNA3.1-Notch后喉乳头状瘤细胞增殖能力和细胞侵袭率较单纯转染miR-577 mimic组明显增加(P<0.05);共转染pcDNA3.1-Notch逆转了miR-577 mimic对喉乳头状瘤细胞增殖、侵袭能力的抑制作用。结论幼儿喉乳头状瘤组织及喉乳头状瘤细胞中miR-577显著低表达,过表达miR-577显著抑制喉乳头状瘤细胞的增殖和侵袭;Notch是miR-577的潜在靶点,miR-577可能通过与Notch的3'UTR区结合进而调控Notch信号通路来抑制喉乳头状瘤细胞的增殖和侵袭。
文摘目的:探讨利用577nm阈值下微脉冲激光治疗糖尿病性黄斑水肿(DME)的临床效果。方法:回顾性分析48例64眼DME患者临床资料,行577nm阈值下微脉冲激光术者26例35眼,行传统格栅样激光术者22例29眼。比较术前及术后1、3、6mo时BCVA(LogMAR)、黄斑中心凹视网膜厚度(CFT)、平均光敏感度(MS)及平均视野缺损(MD)变化,分析两组患者眼底硬性渗出持续时间及并发症。结果:术后1、3、6mo时,两组视力(0.30±0.09 vs 0.35±0.10、0.19±0.07 vs 0.26±0.09、0.13±0.04 vs 0.18±0.05)及CFT (349.26±21.80μm vs 364.37±23.91μm、314.46±20.49μm vs 335.07±22.68μm、328.35±21.74μm vs 352.43±23.60μm)均较术前下降,且观察组明显低于同一时间对照组(均P<0.05);观察组MS、MD水平均较术前提升,且明显高于同一时间对照组5.83±1.16dB vs 4.22±1.04dB、6.38±1.29dB vs 4.49±1.17dB、6.75±1.22dB vs 4.68±1.20dB,-5.53±1.41dB vs-7.66±1.52dB、-5.09±1.30dB vs-7.26±1.39dB、-4.68±1.14dB vs-7.05±1.26dB)(均P<0.05)。观察组眼底硬性渗出持续时间明显少于对照组(3.39±0.80mo vs 4.25±1.14mo)(P<0.05)。术后6mo内,观察组眼球疼痛发生率明显低于对照组[3%(1/35)vs 24%(7/29)](P<0.05),而前房炎性反应、视野缺损、高眼压及角膜水肿发生率比较均无差异(P>0.05)。结论:577nm阈值下微脉冲激光术治疗DME安全有效。
